Galectin Therapeutics and Aratana Therapeutics Look Forward to the 4th Quarter of 2017

NEW YORK, NY / ACCESSWIRE / March 15, 2017 /
The development of a drug and receiving a passing grade from the FDA is not always enough to keep a company financially solvent. Investors are required to be willing to inject a large dose of hope into their choice of biotech stocks. According to BIO, a major trade association that represents biotech companies, “The overall likelihood of approval (LOA) from Phase I for all developmental candidates was 9.6%, and 11.9% for all indications outside of Oncology.” Basically, there is a 1 in 10 chance your investment will pay off.

RDI Initiates
Coverage:

Galectin Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=GALT

Aratana Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=PETX

A positive result from a small scale study on Galectin Therapeutics GR-MD-02 drug caused a 3.3 percent increase in the company’s stock price, up 6 cents to $1.87 a share. The GR-MD-02 drug is designed to target the galectin-3 protein which plays a critical role in the progression of fatty liver disease and fibrosis. The small bump in price is a continuation of a late January rally in the stock as investors are beginning to see the stock in a new light after its initial Phase 2 results caused to the stock to drop dramatically last November. The latest results show the drug to be safe, with one patient responding very positively to the tests. It currently has a price to book (P/B) ratio of 14.96.

Access RDI’s Galectin Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=GALT

Aratana Therapeutics reported a net loss of $23.3 million for the 4th quarter ending December 31, 2016. The loss, combined with the announcement that its revenues were $292,000, resulted in the price of its stock declining $1.32 to $5.63 a share in a couple of days. The 23+ percent drop is largely in part due to the delay of its Entyce drug for oral appetite simulation in dogs, now scheduled to be available for deliver in late 2017. Earlier in February class action lawsuit has been initiated against the company for misleading statements about Entyce regarding manufacturing contracts and timeline for a commercial launch. The company says it has $88 million in cash, sufficient to keep its operations going until the first quarter of 2018. The $292,000 revenue fell far short of Wall Street analyst expectations of $923,000. Aratana is a company that develops drugs for cats and dogs.

Access RDI’s Aratana Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PETX

Our Actionable Research on Galectin Therapeutics Inc. (NASDAQ: GALT) Aratana Therapeutics Inc. (NASDAQ: PETX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457311